Skip to main content
PMC home page
Immunology logoLink to Immunology
. 1975 Jul;29(1):175–184.

Immunosuppresive effect of a human hepatic glycoferroprotein, alpha2H globulin. A study on the transformation of normal human lymphocytes.

D Buffe, C Rimbaut
PMCID: PMC1445880  PMID: 49295

Abstract

A macroglycoferroprotein of hepatic orgin, alpah2H globulin, the serum level of which increases a few weeks or months before local recurrence of metastases, has been essayed for its immunosuppressive activity. The study was carried out using the lymphoblastic transformation test and was judged by tritiated thymidine incorporation and microscopic examination. PHA-induced blast transformation of 97 per cent of normal donor lymphocytes is inhibited by 100 mug/ml of alpha2H globulin. This inhibitory effect is proportional to the quantity of added alpha2H globulin. In is obvious with a concentration of 2-5 mug/ml, a frequently observed level in the serum of patient with tumours. Preincubation of lymphocytes with alpha2H globulin renders more effective the inhibitory action on PHA-induced transformation. A mechanism of competition between PHA and alpha2H globulin is suggested by preincubation and the inhibitory effect related to the doses. However, microscopic observation shows that alpha2H globulin acts on the earliest events occurring to the stimulated lymphocytes, by inhibiting cytoplasmic RNA and protein synthesis. The alpha2H globulin effect may not only have an immunosuppresive activity but it may have a more general effect, for example blocking or modifying cellular respiration.

Full text

PDF
180

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Buffe D., Rimbaut C., Burtin P. Présence d'une protéine d'origine tissulaire, l'alpha 2H-globuline, dans le sérum de sujets atteints d'affections malignes. Int J Cancer. 1968 Nov 15;3(6):850–856. doi: 10.1002/ijc.2910030618. [DOI] [PubMed] [Google Scholar]
  2. Buffe D., Rimbaut C., Fuccaro C., Burtin P. Isolement et caractérisation d'une 2 ferroprotéine: la globuline 2. Ann Inst Pasteur (Paris) 1972 Jul;123(1):29–42. [PubMed] [Google Scholar]
  3. Buffe D., Rimbaut C., Lemerle J., Schweisguth O., Burtin P. Présence d'une ferroprotéine d'origine tissulaire, l'alpha-2H, dans le sérum des enfants porteurs de tumeurs. Int J Cancer. 1970 Jan 15;5(1):85–87. doi: 10.1002/ijc.2910050111. [DOI] [PubMed] [Google Scholar]
  4. Cooperband S. R., Bondevik H., Schmid K., Mannick J. A. Transformation of human lymphocytes: inhibition by homologous alpha globulin. Science. 1968 Mar 15;159(3820):1243–1244. doi: 10.1126/science.159.3820.1243. [DOI] [PubMed] [Google Scholar]
  5. Gatti R. A. Serum inhibitors of lymphocyte responses. Lancet. 1971 Jun 26;1(7713):1351–1352. doi: 10.1016/s0140-6736(71)91906-4. [DOI] [PubMed] [Google Scholar]
  6. Harris R., Ukaejiofo E. O. Rapid preparation of lymphocytes for tissue-typing. Lancet. 1969 Aug 9;2(7615):327–327. doi: 10.1016/s0140-6736(69)90096-8. [DOI] [PubMed] [Google Scholar]
  7. Janossy G., Greaves M. F. Lymphocyte activation. I. Response of T and B lymphocytes to phytomitogens. Clin Exp Immunol. 1971 Oct;9(4):483–498. [PMC free article] [PubMed] [Google Scholar]
  8. Mannick J. A., Schmid K. Prolongation of allograft survival by an alpha globulin isolated from normal blood. Transplantation. 1967 Jul;5(4 Suppl):1231–1238. doi: 10.1097/00007890-196707001-00063. [DOI] [PubMed] [Google Scholar]
  9. Martin J. P., Charlionet R., Ropartz C. L'alpha 2 H sérique au cours des hémopathies malignes et des cirrhoses. Valeur évolutive. Presse Med. 1971 Nov 27;79(51):2313–2316. [PubMed] [Google Scholar]
  10. Nairn R. C., Nind A. P., Guli E. P., Davies D. J., Little J. H., Davis N. C., Whitehead R. H. Anti-tumor immunoreactivity in patients with malignant melanoma. Med J Aust. 1972 Feb 26;1(9):397–403. [PubMed] [Google Scholar]
  11. Nairn R. C., Nind A. P., Guli E. P., Davies D. J., Rolland J. M., McGiven A. R., Hughes E. S. Immunological reactivity in patients with carcinoma of colon. Br Med J. 1971 Dec 18;4(5789):706–709. doi: 10.1136/bmj.4.5789.706. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Nind A. P., Nairn R. C., Rolland J. M., Guli E. P., Hughes E. S. Lymphocyte anergy in patients with carcinoma. Br J Cancer. 1973 Aug;28(2):108–117. doi: 10.1038/bjc.1973.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Raphael S. S., Hyde T. A. Deaf-mutism and type-II hyperlipoproteinaemia. Lancet. 1970 Apr 25;1(7652):892–892. [PubMed] [Google Scholar]
  14. Riggio R. R., Parrillo J. e., Jr, Bull F. G., Schwartz G. H., Stenzel K. H., Rubin A. L. Inhibition of lymphocyte transformation by a placental glycoprotein. Transplantation. 1971 Nov;12(5):400–401. doi: 10.1097/00007890-197111000-00011. [DOI] [PubMed] [Google Scholar]
  15. Rimbaut C., Tilz G. P., Buffe D. Immunochemische Untersuchungen an Seren von Tumorpatienten. Med Klin. 1974 Aug 30;69(35):1399–1401. [PubMed] [Google Scholar]
  16. Roitt I. M., Greaves M. F., Torrigiani G., Brostoff J., Playfair J. H. The cellular basis of immunological responses. A synthesis of some current views. Lancet. 1969 Aug 16;2(7616):367–371. doi: 10.1016/s0140-6736(69)92712-3. [DOI] [PubMed] [Google Scholar]
  17. Trubowitz S., Masek B., Del Rosario A. Lymphocyte response to phytohemagglutinin in Hodgkin's disease, lymphatic leukemia and lymphosarcoma. Cancer. 1966 Dec;19(12):2019–2023. doi: 10.1002/1097-0142(196612)19:12<2019::aid-cncr2820191228>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES